| VERTEX PHARMACEUTICALS Patent applications |
| Patent application number | Title | Published |
|---|
| 20090264623 | SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT - The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same. | 10-22-2009 |
| 20090191555 | HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. | 07-30-2009 |
| 20080318803 | Biomarkers for Monitoring Impdh Pathway Inhibition - The present invention is directed to methods for ameliorating reproductive disorders. More specifically, the present invention describes methods and compositions for using IL-17 in the treatment of various infertility-related defects. | 12-25-2008 |
| 20080267915 | Hcv Ns3-Ns4a Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 10-30-2008 |
